Recent Company News

• 12:35 PM ET Feb 19, 2026
  

  PureTech Health issues press release on previously disclosed FDA and EC orphan drug designations to deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF) (124.0000p, 0)

• 12:27 AM ET Feb 19, 2026
  

  FDA grants orphan drug designation to PureTech Health's deupirfenidone to treat idiopathic pulmonary fibrosis (125.0000p, 0)

• 07:01 AM ET Jan 05, 2026
  

  StreetAccount Summary - European unusual volume traders

• 08:22 PM ET Jan 14, 2026
  

  Transcript Intelligence: PureTech Health at J.P. Morgan Healthcare Conference (135.0000p, 0)

• 02:05 AM ET Dec 18, 2025
  

  PureTech Health appoints interim CEO Robert Lyne as CEO, effective immediately (121.0000p, 0)

• 04:21 AM ET Dec 08, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:06 AM ET Dec 08, 2025
  

  PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis (122.0000p, 0)